



Answer to Photo Quiz: Pulmonary and Cardiovascular Manifestations of SARS-CoV-2 Infection

Isaac H. Solomon,^{a,b}  Robert F. Padera, Jr.^{a,b}

^aDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA

^bDepartment of Pathology, Harvard School of Medicine, Boston, Massachusetts, USA

KEYWORDS pulmonary embolism, SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was found to be present by reverse transcriptase PCR (RT-PCR) targeting N1 and N2 gene products, performed by the Massachusetts Department of Public Health on a postmortem nasopharyngeal swab (1), confirming the diagnosis of coronavirus disease 2019 (COVID-19). In addition, immunohistochemistry performed at Brigham and Women's Hospital, using a rabbit polyclonal antibody targeting the severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid (NB100-56576; Novus Biologicals, Centennial, CO) (2), was strongly positive in pneumocytes as well as occasional histiocytes, supporting COVID-19 as the etiology of the diffuse alveolar damage.

SARS-CoV-2 is a betacoronavirus, thought to have originated from bats, that was first recognized in Wuhan, China, in December 2019 and has since been declared a worldwide pandemic, with >5 million confirmed cases and >300,000 deaths as of May 2020 (<https://coronavirus.jhu.edu/map.html>; accessed 23 May 2020). Virus is spread primarily through the inhalation of respiratory droplets or aerosolized particles and can be spread by asymptomatic/presymptomatic individuals, allowing for efficient dissemination among a nonimmune population. Older adults, people living in nursing homes, and individuals with severe comorbidities, including pulmonary disease, cardiovascular disease, diabetes mellitus, and severe obesity, are at the highest risk for severe COVID-19, often requiring mechanical ventilation and resulting in death. Laboratory confirmation typically occurs by RT-PCR on nasopharyngeal swabs, while serology is more useful later in the disease course and for epidemiological purposes (3).

The mechanisms underlying SARS-CoV-2 pathogenesis are incompletely understood. Virus utilizes host angiotensin-converting enzyme 2 (ACE2) for cellular uptake and transmembrane protease serine 2 (TMPRSS2) for priming of the viral spike protein, and viral tropism is thought to be dependent on the expression levels of these two genes (4). Insights have been gained from initial autopsy case series, which show the highest concentration of virus and disease burden in the lungs, consisting of diffuse alveolar damage, microthrombosis, occasional bronchopneumonia, and pulmonary embolism (2, 5). Additional sites of damage include heart, liver, brain, and kidneys, which generally lack significant inflammation or necrosis, and this damage is likely due to a combination of cytokine storm, microthrombosis, hypoxemia, and ischemia rather than a direct effect of viral infection. There are no characteristic viral cytopathic effects associated with SARS-CoV-2 infection, and it is important not to mistake prominent reactive nuclei or internalized cellular debris for viral inclusions, especially within the lung. Due to the overlap of histological features with other infectious (including SARS-CoV and Middle East respiratory syndrome coronavirus) and noninfectious causes of diffuse alveolar damage, this diagnosis requires sufficient clinical suspicion with confirmation by ancillary techniques such as immunohistochemistry or RT-PCR. SARS-CoV-2 infection can cooccur with other respiratory bacterial and viral infections, further

Citation Solomon IH, Padera RF, Jr. 2020. Answer to Photo Quiz: Pulmonary and cardiovascular manifestations of SARS-CoV-2 infection. *J Clin Microbiol* 58:e01108-20. <https://doi.org/10.1128/JCM.01108-20>.

Editor Erik Munson, Marquette University

Copyright © 2020 American Society for Microbiology. All Rights Reserved.

Address correspondence to Robert F. Padera, Jr., rpadera@bwh.harvard.edu.

See <https://doi.org/10.1128/JCM.01107-20> in this issue for photo quiz case presentation.

Published 23 July 2020

complicating the histological differential. Thrombi are generally not subtle and can be recognized microscopically by pale eosinophilic material occluding a blood vessel lumen. Coagulopathy in COVID-19 is associated with increased risk of death, with laboratory testing revealing increased levels of D-dimer, lactate dehydrogenase, and ferritin (6). Whether increased rates of pulmonary embolism are due to specific effects of the virus has yet to be resolved (7).

REFERENCES

1. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, Lynch B, Malapati L, Burke SA, Harcourt J, Tamin A, Thornburg NJ, Villanueva JM, Lindstrom S. 12 May 2020. US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2. *Emerg Infect Dis* <https://doi.org/10.3201/eid2608.201246>.
2. Martines RB, Ritter JM, Matkovic E, Gary J, Bollweg BC, Bullock H, Goldsmith CS, Silva-Flannery L, Seixas JN, Reagan-Steiner S, Uyeki T, Denison A, Bhatnagar J, Shieh WJ, Zaki SR, COVID-19 Pathology Working Group. 21 May 2020. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. *Emerg Infect Dis* <https://doi.org/10.3201/eid2609.202095>.
3. Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, St George K, Smith TC, Bertuzzi S. 26 March 2020. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: value of diagnostic testing for SARS-CoV-2/COVID-19. *mBio* <https://doi.org/10.1128/mBio.00722-20>.
4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 181:271–280. <https://doi.org/10.1016/j.cell.2020.02.052>.
5. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, Bassetti S, Leuppi JD, Cathomas G, Tolnay M, Mertz KD, Tzankov A. 4 May 2020. Post-mortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. *Histopathology* <https://doi.org/10.1111/his.14134>.
6. Levi M, Thachil J, Iba T, Levy JH. 11 May 2020. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol* [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9).
7. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K, Bargfrieder U, Trauner M. 14 May 2020. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. *Ann Intern Med* <https://doi.org/10.7326/M20-2566>.